| Author, Year, Followup,a Pain Duration, Study Quality | Intervention | Population | Function and Pain Outcomes | Other Outcomes |
|---|---|---|---|---|
Abbott, 201347 9.75 months Duration of pain: 9 months Fair | A. Exercise therapy (n=51/22 hip OA): 7 sessions of strengthening, stretching, and neuromuscular control over 9 weeks, with 2 booster sessions at week 16. Individual exercises prescribed as needed. Home exercise prescribed 3 times weekly B. Usual care (n=51/23 hip OA): Routine care provided by patient’s own GP and other healthcare providers | A vs. B (total population, includes knee OA) Age: 67 vs. 66 Females: 49% vs. 63% % hip OA: 43.1% vs. 45.1% WOMAC (0-240): 95.5 vs. 93.8 | A vs. B (hip OA only) 9.75 months WOMAC mean change from baseline: −12.4 vs. 6.6 | NR |
Juhakoski, 201172 3, 9, and 21 months Duration of pain: Mean 8.3 to 8.5 years Fair | A. Exercise + usual care (n=57): 12 strengthening and stretching exercise sessions of 45 minutes once per week, with 4 booster sessions 1 year later B. Usual care (n=56): normal routine care offered by patient’s own GP. All patients attended an hour-long session on basic principles of nonoperative treatment of hip OA | A vs. B Age: 67 vs. 66 years Female: 68% vs. 72% Duration of pain: 8.3 to 8.5 years Baseline WOMAC function (0-100): 24.7 vs. 28.9 Baseline WOMAC pain (0-100): 21.5 vs. 29.1 | A vs. B 3 months WOMAC function: 22.6 vs. 30.1, (difference −7.5, 95% CI −13.9 to −1.0) WOMAC pain: 23.4 vs. 28.9 (difference −5.5, 95% CI −13.0 to 2.0) 9 months WOMAC function: 24.6 vs. 27.6 (difference −3.0, 95% CI −9.2 to 3.2) WOMAC pain: 22.9 vs. 25.0 (difference −2.1, 95% CI −9.2 to 5.0) 21 months WOMAC function: 24.4 vs. 30.0 (difference −5.6, 95% CI −12.9 to 1.7) WOMAC pain: 24.1 vs. 27.9 (difference −3.8, 95% CI −12.0 to 4.4) | A vs. B 3 months Weak opioidb use (p=0.73): Not using: 82.5% vs. 87.7% 1-6 times/week: 10.5% vs. 8.8% Daily: 7.0% vs. 3.5% 9 months Mean doctor visits for hip OA: 0.5 vs. 0.8, p=0.07 Mean physiotherapy visits for hip OA: 1.3 vs. 2.0, p=0.05 Weak opioidb use (p=0.12): Not using: 81.0% vs. 93.1% 1-6 times/week: 10.4% vs. 1.7% Daily: 8.6% vs. 5.2% 21 months Mean doctor visits (between 9 and 21 month followup) for hip OA: 0.5 vs. 1.1, p=0.05 Mean physiotherapy visits (between 9 and 21 month followup) for hip OA: 0.4 vs. 1.3, p<0.001 Weak opioidb use (p=0.70): Not using: 80.7% vs. 85.2% 1-6 times/week: 12.3% vs. 7.4% Daily: 7.0% vs. 7.4% |
6 months, 3 years Duration of pain: NR Poor | A. Exercise (n=45): Eight weekly group sessions of strength training, information on a home exercise program, ergonomic advice, and dietary advice B. Usual care (n=49): Subject-initiated contact with GP. Reference group (n=NR) consisting of weekly stress management sessions for 10 weeks | A vs. B Age: 68 vs. 69 Female: 64% vs. 71% Baseline HHS (0-100): 71.1 vs. 71.0 Baseline GARS (18-72): 22.8 vs. 25.3 Baseline SIP-136 physical (0-100): 7.2 vs. 7.6 Baseline pain VAS (0-10): 3.8 vs. 4.2 Baseline HHS pain subscale (0-44): 27.9 vs. 28.8 | A vs. B 3 months HHS: 75.4 vs. 71.1, (difference 4.3, 95% CI −2.2 to 10.8) GARS: 23.7 vs. 26.3, (difference −2.6, 95% CI −6.0 to 0.8) SIP-136 physical: 5.1 vs. 8.4, (difference −3.3, 95% CI −5.3 to −1.3) Pain VAS: 3.5 vs. 5.1, (difference −1.6, 95% CI −2.6 to −0.6) HHS pain subscale: 29.6 vs. 26.9, (difference −0.9, 95% CI −4.7 to 2.9) | A vs. B 3 months QoL VAS (0-10): 5.0 vs. 4.2, (difference 1.4, 95% CI −0.2 to 3.0) HRQoL (7-39): 28.6 vs. 27.3, (difference 0.9, 95% CI −0.4 to 2.2) |
Teirlinck, 201674 3 and 9 months Duration of pain: Median 1 year Fair | A. Exercise therapy (n=101): 12 sessions over 3 months consisting of strengthening, stretching, and aerobic exercise B. Usual care (n=102): Routine care provided by patient’s own GP | A vs. B Age: 64 vs. 67 Females: 62% vs. 55% Pain duration median (IQR): 365 (810) vs. 365 (819) days Baseline HOOS function (0-100): 35.4 vs. 32.2 Baseline HOOS pain (0-100): 37.6 vs. 38.9 Baseline ICOAP constant pain (0-20): 5.4 vs. 5.8 Baseline ICOAP intermittent pain (0-24): 8.0 vs. 8.4 Baseline ICOAP total pain (0-100): 30.4 vs. 32.2 | A vs. B 3 months HOOS function: 30.8 vs. 35.3, (adjusted difference −2.4, 95% CI −6.7 to 1.9) HOOS pain: 34.4 vs. 37.2, (adjusted difference −2.2, 95% CI −6.2 to 1.7) ICOAP constant pain: 4.0 vs. 5.3, (adjusted difference −0.9, 95% CI −1.9 to 0.1) ICOAP intermittent pain: 7.0 vs. 7.9, (adjusted difference −0.6, 95% CI −1.7 to 0.6) ICOAP total pain: 24.9 vs. 29.8, (adjusted difference −3.3, 95% CI −8.0 to 1.4) 9 months HOOS function: 26.8 vs. 34.2, (adjusted difference −3.0, 95% CI −6.7 to 0.2) HOOS pain: 31.6 vs. 34.6, (adjusted difference −1.6, 95% CI −6.2 to 3.0) ICOAP constant pain: 3.6 vs. 4.7, (adjusted difference −0.7, 95% CI −1.7 to 0.4) ICOAP intermittent pain: 6.1 vs. 7.2, (adjusted difference −0.6, 95% CI −1.8 to 0.6) ICOAP total pain: 22.2 vs. 27.0, (adjusted difference −2.8, 95% CI −7.6 to 2.0) | A vs. B 3 months EuroQol 5D−3L (−0.329−1.0): 0.77 vs. 0.76, (adjusted difference −0.01, 95% CI −0.06 to 0.04) 9 months EuroQol 5D-3L: 0.78 vs. 0.78, (adjusted difference −0.01, 95% CI −0.06 to 0.04) Total hip replacements: 6 vs. 9 |
CI = confidence interval; GARS = gait abnormality rating scale; GP = general practitioner; HHS = Harris Hip Score; HOOS = hip disability and osteoarthritis outcome score; HRQoL = Health Related Quality of Life; ICOAP = intermittent and constant pain score; IQR = Inter-quartile range; NR = not reported; OA = osteoarthritis; QoL = quality of life; SIP-136 = Sickness Impact Profile-136; VAS = visual analog scale; WOMAC= Western Ontario and McMaster Universities Osteoarthritis Index
Unless otherwise noted, followup time is calculated from the end of the treatment period
Authors defined weak opioids as tramadol or codeine
Cluster RCT where clusters were formed from participants selecting a time that best fit their schedule
From: Results
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.